Multiscale, mechanistic model of Rheumatoid Arthritis to enable decision making in late stage drug development

An integrated quantitative systems pharmacology virtual population approach for calibration with oncology efficacy endpoints

Quantitative systems pharmacology model of erythropoiesis to simulate therapies targeting anemia due to chronic kidney disease

Can a propensity score matching method be applied to assessing efficacy from single-arm proof-of-concept trials in oncology?

Tumor dynamics in patients with solid tumors treated with pembrolizumab beyond disease progression

Beyond the single average tumor: Understanding IO combinations using a clinical QSP model that incorporates heterogeneity in patient response.

Estimating Smoking Cessation Rates and Smoking Prevalences Using Public Data and a Published Dynamic Model.

Lesion-level heterogeneity of radiologic progression in patients treated with pembrolizumab.

Incorporating lesion-to-lesion heterogeneity into early oncology decision making.

Hallmarks of neurodegenerative disease: A systems pharmacology perspective.